Vivos (RDGL) Return on Capital Employed (2011 - 2025)
Vivos (RDGL) reported Return on Capital Employed of 161.19% for Q4 2025, down 361.0% on a YoY basis from 61.76% in Q4 2024, and down 42.99% sequentially from 112.73% in Q3 2025.
Vivos (RDGL) Return on Capital Employed (2011 - 2025) Analysis & Trends
Vivos (RDGL) has 15 years of Return on Capital Employed data on file, last reported at 161.19% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 361.0% year-over-year to 161.19%; the trailing twelve-month figure through Dec 2025 stood at 161.19% (down 361.0% YoY), and the FY2025 full-year result was 163.77%, down 2189.0% from the prior year.
- Return on Capital Employed slipped to 161.19% in Q4 2025, from 112.73% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 75.62% in Q1 2021 to a low of 219.63% in Q1 2024.
- A 5-year average of 156.53% and a median of 153.6% in 2021 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 31454 bps in 2021 and soared 11064 bps in 2025, its largest moves.
- Tracing RDGL's Return on Capital Employed over 5 years: stood at 149.62% in 2021, then climbed by 7 bps to 138.89% in 2022, then sank by 50 bps to 207.93% in 2023, then increased by 24 bps to 157.59% in 2024, then decreased by 2 bps to 161.19% in 2025.
- Business Quant data shows RDGL's Return on Capital Employed at 161.19% in Q4 2025, 112.73% in Q3 2025, and 103.43% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 24.24% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 9.30% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 8.38% |
| 10 | Vivos | 27.16 Mn | 25.60 Mn | -3,105.00 | -161.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -161.19% |
| Sep 30, 2025 | -112.73% |
| Jun 30, 2025 | -103.43% |
| Mar 31, 2025 | -108.99% |
| Dec 31, 2024 | -157.59% |
| Sep 30, 2024 | -197.88% |
| Jun 30, 2024 | -193.68% |
| Mar 31, 2024 | -219.63% |
| Dec 31, 2023 | -207.93% |
| Sep 30, 2023 | -162.73% |
| Jun 30, 2023 | -141.81% |
| Mar 31, 2023 | -129.96% |
| Dec 31, 2022 | -138.89% |
| Sep 30, 2022 | -143.38% |
| Jun 30, 2022 | -196.20% |
| Mar 31, 2022 | -217.54% |
| Dec 31, 2021 | -149.62% |
| Sep 30, 2021 | -169.77% |
| Jun 30, 2021 | -142.05% |
| Mar 31, 2021 | -75.62% |